Lexicon Story

<div class='circular--portrait' style='background:#169D0B;color: #E6E6FA;font-size:4em;'>LP</div>
LXRX -- USA Stock  

USD 1.54  0.09  6.21%

As many millenniums are trying to avoid healthcare space, it makes sense to break down Lexicon Pharmaceuticals a little further and try to understand its current market patterns. As expected, Lexicon Pharmaceuticals is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The company returns are correlated to returns on the market. As market fluctuates, the company is expected to follow. The appearance of strong fundamental indicators of the company suggests a short-term price swing for investors of Lexicon. Lexicon Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 5th of November 2020. The stock experiences an active upward rally.
Published over a month ago
View all stories for Lexicon Pharmaceuticals | View All Stories
Is Lexicon Pharmaceuticals (NASDAQ:LXRX) about to rebound?
This firm's average rating is Hold from 4 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Lexicon Pharmaceuticals market sentiment investors' perception of the future value of Lexicon. Let us look at a few aspects of Lexicon technical analysis. The company has Profit Margin (PM) of 26.59 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 38.99 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.39.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Lexicon Pharmaceuticals. In general, we focus on analyzing Lexicon Pharmaceuticals stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lexicon Pharmaceuticals's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Lexicon Pharmaceuticals's intrinsic value. In addition to deriving basic predictive indicators for Lexicon Pharmaceuticals, we also check how macroeconomic factors affect Lexicon Pharmaceuticals price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Lexicon Stands against Peers?

Analyzing Lexicon Pharmaceuticals competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Lexicon Pharmaceuticals across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Lexicon Pharmaceuticals Competition Details

How Lexicon utilizes its cash?

To perform a cash flow analysis of Lexicon Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Lexicon Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Lexicon Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Lexicon Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Lexicon Pharmaceuticals reported Net Cash Flow from Operations of 113.81 Million in 2019

Purchase by Raymond Debbane of 3400 shares of Lexicon Pharmaceuticals

Legal trades by Lexicon Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Lexicon Pharmaceuticals insider trading alert for perchase of common stock by Raymond Debbane, the corporate stakeholder, on 17th of June 2020. This event was filed by Lexicon Pharmaceuticals I with SEC on 2019-09-17. Statement of changes in beneficial ownership - SEC Form 4. Raymond Debbane is currently serves as independent chairman of the board of Lexicon Pharmaceuticals [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Lexicon Pharmaceuticals valued reasonably by the market?

The company has a beta of 0.911. Let's try to break down what Lexicon's beta means in this case. Lexicon Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Lexicon Pharmaceuticals is expected to follow. The beta indicator helps investors understand whether Lexicon Pharmaceuticals moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Lexicon deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The small slide in market price for the last few months may encourage investors to take a closer look at the firm as it closed today at a share price of 1.81 on 16,723,245 in trading volume. The company management teams did not add much value to Lexicon Pharmaceuticals investors in June. However, diversifying your holdings with Lexicon Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.72. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Lexicon Pharmaceuticals partners.

Our perspective of the current Lexicon Pharmaceuticals rise

The total risk alpha is down to -0.58 as of today. Lexicon Pharmaceuticals exhibits very low volatility with skewness of 0.54 and kurtosis of 1.61. However, we advise investors to further study Lexicon Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Bottom Line On Lexicon Pharmaceuticals

While some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Lexicon Pharmaceuticals may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither purchase new shares of Lexicon nor drop your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Lexicon Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Lexicon Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com